Compositions and methods for treatment of cachexia

• US 8,080,528 B2
• Filed: 12/20/2006
• Issued: 12/20/2011
• Est. Priority Date: 12/22/2005
• Status: Expired due to Fees

• Current Assignee: The Releef Initiative
• Original Assignee: The Releef Initiative
• Inventors: Kenley, Richard, Ekblom, Jonas, Denissenko, Mikhail
• Primary Examiner(s): Peselev, Elli
• Application Number:
  US11/614,056
• Publication Number:
  US 20070149465A1
• Time in Patent Office: 1,826 Days
• Field of Search: None
• US Class Current: 514/29
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Compositions and methods for preventing and treating wasting disorders, such as cachexia and anorexia, are provided. In one aspect, the present invention provides a method for preventing and treating a wasting disorder in a mammal. In one embodiment, the method of the invention comprises administering to such mammal a macrolide and a β_2-adrenergic agonist in combination such that the macrolide and said β_2-agonist are administered in amounts effective to prevent or at least alleviate said wasting disorder.

Claims

1. A method for treating cancer-related cachexia in a mammal, comprising administering to such mammal a macrolide and a β

₂-agonist in combination, wherein said macrolide and said β

₂-agonist are administered in the same pharmaceutically acceptable carrier, said macrolide is roxithromycin, said roxithromycin is administered at a dose of between about 50 mg/d and about 200 mg/d, and wherein said β

₂-agonist is formoterol fumarate.

2. The method of claim 1, wherein said formoterol fumarate is administered at a dose between about 5 μ

g/d and about 500 μ

g/d.

3. The method of claim 2, wherein said formoterol fumarate is administered at a dose between about 5 μ

g/d and about 240 μ

g/d.